PHIO News and Press, Phio Pharmaceuticals Corp. From 05/14/25

2025-05-14 18:48:08 ET Phio Pharmaceuticals Corp. (PHIO) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.84%. The average open to low on the day of earnings was -6.17%. The average ope...

2025-05-14 18:43:07 ET Phio Pharmaceuticals Corp. (PHIO) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PHIO stock price following earnings has averaged ±2.13% , with a median of 1.54...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10th ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Routine medical appointments or cancer screening rates—an important aspect in increasing survival rates—have sunk to just over half of the populat...

2025-04-09 11:50:00 ET A biotech company based out of Massachusetts is turning heads so far during Wednesday’s session after the company announced its Safety Monitory Committee recommended dose escalation in its Phase 1b trial of PH-762. Naturally traders rushed to buy up sha...

2025-04-09 11:18:13 ET Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is one of today’s top gainers. The company’s shares have moved 49.5% on the day to $1.51. Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeut...

2025-04-09 09:00:55 ET DENVER, Colo., Apr 09, 2025 ( 247marketnews.com )- Phio Pharmaceuticals (NASDAQ:PHIO) reports positive data from its INTASYL PH-762 skin cancer trial. Announced today, the Safety Monitoring Committee (SMC) gave a green light to crank PH-762’s Phase 1b trial...

-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - April 9, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutica...

To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary I...